{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:02:11Z","timestamp":1787162531123,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jconrel.2024.02.004","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T16:31:05Z","timestamp":1708533065000},"page":"84-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Biomimetic nano-chelate diethyldithiocarbamate Cu\/Fe for enhanced metalloimmunity and ferroptosis activation in glioma therapy"],"prefix":"10.1016","volume":"368","author":[{"given":"Rui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiwan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.02.004_bb0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(05)70118-6","article-title":"Surgery for malignant gliomas: mechanistic reasoning and slippery statistics","volume":"4","author":"Mitchell","year":"2005","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0010","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1586\/14737140.6.8.1187","article-title":"Temozolomide: a milestone in neuro-oncology and beyond?","volume":"6","author":"Mutter","year":"2006","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0015","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin (R)) as treatment of recurrent glioblastoma Multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12967-023-04042-5","article-title":"Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma","volume":"21","author":"Hou","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0035","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.trecan.2019.07.008","article-title":"Population dynamics in cell death: mechanisms of propagation","volume":"5","author":"Riegman","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100916","article-title":"Overcoming cancer chemotherapy resistance by the induction of ferroptosis","volume":"66","author":"Wang","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0045","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jconrel.2020.01.008","article-title":"Ferroptosis-driven nanotherapeutics for cancer treatment","volume":"319","author":"Shan","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0050","article-title":"Ferroptosis and its potential role in glioma: from molecular mechanisms to therapeutic opportunities","volume":"11","author":"Luo","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0055","first-page":"599","article-title":"Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy, protein","volume":"12","author":"Koppula","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0060","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2023.09.024","article-title":"Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer","volume":"363","author":"Ding","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.818453","article-title":"Targeting Cancer cell Ferroptosis to reverse immune checkpoint inhibitor therapy resistance","volume":"10","author":"Deng","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0075","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1016\/j.apsb.2022.11.001","article-title":"Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy","volume":"12","author":"Xu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121335","article-title":"Leveraging disulfiram to treat cancer: mechanisms of action, delivery strategies, and treatment regimens","volume":"281","author":"Lu","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.ai.2019.11.007","article-title":"Metalloimmunology: the metal ion-controlled immunity","volume":"145","author":"Wang","year":"2020","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0090","doi-asserted-by":"crossref","first-page":"7190","DOI":"10.2174\/0929867328666210324161205","article-title":"Metal toxicity and speciation: a review","volume":"28","author":"Peana","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121880","article-title":"Disulfiram loaded calcium phosphate nanoparticles for enhanced cancer immunotherapy","volume":"291","author":"Li","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41467-020-14338-5","article-title":"Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties","volume":"11","author":"Terashima","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0105","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1074\/jbc.274.11.7011","article-title":"Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier","volume":"274","author":"Fillebeen","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0110","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1016\/S0021-9258(17)37571-3","article-title":"Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins","volume":"269","author":"Schnitzer","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0115","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1039\/C7SC04853J","article-title":"Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy","volume":"9","author":"Zhao","year":"2018","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0120","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ccr.2013.01.031","article-title":"Emerging protein targets for metal-based pharmaceutical agents: an update","volume":"257","author":"de Almeida","year":"2013","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0125","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0135","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1080\/15548627.2023.2165323","article-title":"Copper-dependent autophagic degradation of GPX4 drives ferroptosis","volume":"19","author":"Xue","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0140","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bbrc.2019.01.090","article-title":"The release and activity of HMGB1 in ferroptosis","volume":"510","author":"Wen","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101481","article-title":"The role of dendritic cells in cancer and anti-tumor immunity","volume":"52","author":"Marciscano","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0150","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.immuni.2022.04.016","article-title":"Dendritic cells can prime anti-tumor CD8(+) T cell responses through major histocompatibility complex cross-dressing","volume":"55","author":"MacNabb","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0155","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","article-title":"Metabolic regulation of T cell longevity and function in tumor immunotherapy","volume":"26","author":"Kishton","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0160","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41418-020-00728-1","article-title":"Cellular degradation systems in ferroptosis","volume":"28","author":"Chen","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0165","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.freeradbiomed.2018.09.014","article-title":"Role of GPX4 in ferroptosis and its pharmacological implication","volume":"133","author":"Seibt","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0170","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0175","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","article-title":"The role of ROS in tumour development and progression","volume":"22","author":"Cheung","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0180","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jconrel.2023.07.050","article-title":"Ferritin-nanocaged copper arsenite minerals with oxidative stress-amplifying activity for targeted cancer therapy","volume":"361","author":"Lee","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0185","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","article-title":"Broadening horizons: the role of ferroptosis in cancer","volume":"18","author":"Chen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0190","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.tcb.2020.02.009","article-title":"Emerging mechanisms and disease relevance of Ferroptosis","volume":"30","author":"Stockwell","year":"2020","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0195","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0200","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2021.11.028","article-title":"Nanomaterials targeting tumor associated macrophages for cancer immunotherapy","volume":"341","author":"Zhao","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0205","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jconrel.2020.10.052","article-title":"Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity","volume":"329","author":"Zhao","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0210","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nature25016","article-title":"Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4","volume":"552","author":"Skrott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0215","doi-asserted-by":"crossref","first-page":"41118","DOI":"10.1021\/acsami.8b14940","article-title":"Disulfiram copper nanoparticles prepared with a stabilized metal ion ligand complex method for treating drug-resistant prostate cancers","volume":"10","author":"Chen","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00775-018-1628-7","article-title":"The interplay between copper(II), human serum albumin, fatty acids, and carbonylating agent interferes with Cys 34 thiol reactivity and copper binding","volume":"24","author":"Penezic","year":"2019","journal-title":"J. Biol. Inorg. Chem."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0225","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1021\/acs.molpharmaceut.6b01074","article-title":"Design of an Anticancer Copper(II) prodrug based on the Lys199 residue of the active targeting human serum albumin nanoparticle carrier","volume":"14","author":"Gou","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0230","article-title":"Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer","volume":"18","author":"Chang","year":"2020","journal-title":"Appl. Mater. Today"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101448","article-title":"Anti-alcoholism drug disulfiram for targeting glioma energy metabolism using BBB-penetrating delivery of fixed-dose combination","volume":"44","author":"Zhao","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/jcbfm.2012.153","article-title":"Immunologic privilege in the central nervous system and the blood-brain barrier","volume":"33","author":"Muldoon","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0245","doi-asserted-by":"crossref","first-page":"eabo7649","DOI":"10.1126\/science.abo7649","article-title":"Transforming the understanding of brain immunity","volume":"380","author":"Castellani","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0250","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0260","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0265","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0306-9877(88)90155-7","article-title":"Erythrocytosis: a key to understanding the hemodynamic changes in hypertension","volume":"27","author":"Gaar","year":"1988","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0270","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1038\/s41467-021-27414-1","article-title":"Molecular basis for redox control by the human cystine\/glutamate antiporter system xc","volume":"12","author":"Parker","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.02.004_bb0275","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0280","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jconrel.2023.05.024","article-title":"Targeting lactate metabolism and immune interaction in breast tumor via protease-triggered delivery","volume":"358","author":"Zhao","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.02.004_bb0285","first-page":"e2303916","article-title":"Mitigation of anti-drug antibody production for augmenting anticancer efficacy of therapeutic protein via co-injection of nano-rapamycin","author":"Chang","year":"2023","journal-title":"Small"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T16:33:49Z","timestamp":1738082029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924000919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":57,"alternative-id":["S0168365924000919"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.02.004","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomimetic nano-chelate diethyldithiocarbamate Cu\/Fe for enhanced metalloimmunity and ferroptosis activation in glioma therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}